DK1356822T3 - Farmaceutiske sammensætninger, der forøger immunogeniteten af svagt immunogene antigener - Google Patents

Farmaceutiske sammensætninger, der forøger immunogeniteten af svagt immunogene antigener

Info

Publication number
DK1356822T3
DK1356822T3 DK01999387.2T DK01999387T DK1356822T3 DK 1356822 T3 DK1356822 T3 DK 1356822T3 DK 01999387 T DK01999387 T DK 01999387T DK 1356822 T3 DK1356822 T3 DK 1356822T3
Authority
DK
Denmark
Prior art keywords
immunogenicity
enhance
pharmaceutical compositions
immunogenic antigens
weakly immunogenic
Prior art date
Application number
DK01999387.2T
Other languages
English (en)
Inventor
Ramirez Belinda Sanchez
Pestana Eduardo Raul Suarez
La Barrera Aira Anabel De
Pardillo Circe Mesa
Leon Delgado Joel De
Rodriguez Yildian Diaz
Rodriguez Rolando Perez
Molina Luis Enrique Fernandez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU20000285A external-priority patent/CU23000A1/es
Priority claimed from CU20010167A external-priority patent/CU23009A1/es
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Application granted granted Critical
Publication of DK1356822T3 publication Critical patent/DK1356822T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK01999387.2T 2000-12-06 2001-12-06 Farmaceutiske sammensætninger, der forøger immunogeniteten af svagt immunogene antigener DK1356822T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20000285A CU23000A1 (es) 2000-12-06 2000-12-06 Composiciones vacunales para la inmunoterapia activa específica del cáncer
CU20010167A CU23009A1 (es) 2001-07-12 2001-07-12 Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos
PCT/CU2001/000010 WO2002045746A2 (es) 2000-12-06 2001-12-06 Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos

Publications (1)

Publication Number Publication Date
DK1356822T3 true DK1356822T3 (da) 2011-02-07

Family

ID=38812545

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01999387.2T DK1356822T3 (da) 2000-12-06 2001-12-06 Farmaceutiske sammensætninger, der forøger immunogeniteten af svagt immunogene antigener

Country Status (20)

Country Link
US (1) US7776342B2 (da)
EP (1) EP1356822B1 (da)
JP (1) JP4210519B2 (da)
KR (1) KR100850473B1 (da)
CN (1) CN1291755C (da)
AR (1) AR031638A1 (da)
AT (1) ATE485833T1 (da)
AU (2) AU2002221519B2 (da)
BR (1) BRPI0116013B8 (da)
CA (1) CA2431188C (da)
DE (1) DE60143363D1 (da)
DK (1) DK1356822T3 (da)
EA (1) EA005138B1 (da)
HK (1) HK1063726A1 (da)
MX (1) MXPA03005032A (da)
NZ (1) NZ526282A (da)
PE (1) PE20020572A1 (da)
UY (1) UY27059A1 (da)
WO (1) WO2002045746A2 (da)
ZA (1) ZA200304411B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1367395A1 (de) * 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
EP1358910A1 (de) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
CU23257A1 (es) * 2003-02-27 2008-01-24 Centro Inmunologia Molecular COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
AR045815A1 (es) * 2003-10-09 2005-11-16 Ct Ingenieria Genetica Biotech Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano
WO2005111079A2 (en) * 2004-05-14 2005-11-24 The United States Of America As Represented By The Secretary Department Of Health And Human Services Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
CA2728374A1 (en) * 2008-06-17 2010-01-14 Universite Laval Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines
NZ612285A (en) * 2010-12-22 2015-09-25 Bayer Ip Gmbh Enhanced immune response in bovine species
KR101323845B1 (ko) * 2011-01-21 2013-10-31 광주과학기술원 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
MX2015012461A (es) * 2013-03-15 2016-08-08 Bioven 3 Ltd Proteinas sintéticas autoensamblables.
CU24299B1 (es) * 2013-08-02 2017-12-08 Centro De Inmunología Molecular Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
HK1194912A2 (en) * 2013-09-17 2014-10-24 Bestop Group Holdings Ltd Growth factor concentrate and the use thereof
US10105306B2 (en) * 2013-09-17 2018-10-23 Bestop Group Holdings Limited Method of preparing a growth factor concentrate
EP3116893B1 (en) * 2014-03-11 2019-08-28 Jacques Fantini A chimeric peptide that interacts with cell membrane gangliosides
AU2018234783A1 (en) 2017-03-15 2019-10-10 Centro De Inmunologia Molecular Method for the treatment of patients with carcinomas
EP3688026A4 (en) * 2017-09-27 2021-11-10 L2 Diagnostics, LLC PHARMACEUTICAL AND VACCINAL COMPOSITIONS BASED ON PEPTIDE ERBB AND THEIR THERAPEUTIC USES FOR THE TREATMENT OF CANCER
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras
CN109865137A (zh) * 2019-01-23 2019-06-11 天德悦（北京）生物科技有限责任公司 经碘代乙酰基活化的琼脂糖微球在提高多肽或蛋白类免疫原免疫原性中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
IT1206250B (it) * 1987-02-18 1989-04-14 Ist Farmacoterapico It Spa Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
WO1994001133A1 (en) 1992-07-08 1994-01-20 Schering Corporation Use of gm-csf as a vaccine adjuvant
ES2166770T3 (es) * 1993-12-09 2002-05-01 Centro Inmunologia Molecular Anticuerpos monoclonales contra gangliosidos y sus utilizaciones en la inmunoterapia activa especifica de tumores malignos.
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1999036085A1 (en) * 1998-01-16 1999-07-22 Biomira Usa Inc. Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes

Also Published As

Publication number Publication date
EP1356822B1 (en) 2010-10-27
UY27059A1 (es) 2002-04-26
BRPI0116013B1 (pt) 2018-07-24
JP2004523494A (ja) 2004-08-05
CN1484532A (zh) 2004-03-24
AU2002221519B2 (en) 2006-11-23
CN1291755C (zh) 2006-12-27
US7776342B2 (en) 2010-08-17
HK1063726A1 (en) 2005-01-14
BR0116013A (pt) 2004-01-06
MXPA03005032A (es) 2004-09-10
ATE485833T1 (de) 2010-11-15
KR100850473B1 (ko) 2008-08-07
WO2002045746A2 (es) 2002-06-13
BRPI0116013B8 (pt) 2021-05-25
US20020136735A1 (en) 2002-09-26
PE20020572A1 (es) 2002-07-31
EA200300640A1 (ru) 2003-12-25
ZA200304411B (en) 2004-07-29
AR031638A1 (es) 2003-09-24
CA2431188C (en) 2010-09-07
JP4210519B2 (ja) 2009-01-21
AU2151902A (en) 2002-06-18
NZ526282A (en) 2005-01-28
KR20030061838A (ko) 2003-07-22
DE60143363D1 (de) 2010-12-09
WO2002045746A3 (es) 2002-12-27
CA2431188A1 (en) 2002-06-13
EA005138B1 (ru) 2004-12-30
EP1356822A2 (en) 2003-10-29

Similar Documents

Publication Publication Date Title
DK1356822T3 (da) Farmaceutiske sammensætninger, der forøger immunogeniteten af svagt immunogene antigener
DK1326585T3 (da) Fremgangsmåde til fremstilling af pulverformuleringer
DK1390066T3 (da) Vaccinesammensætning
NO20026175L (no) Vaksinesammensetning
ATE321569T1 (de) Kombinierte impfstoffzusammensetzungen
CY2013036I2 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
NO20052010D0 (no) Immunogen sammensetning
NO20035208D0 (no) Nytt vaksine preparat
ATE490327T1 (de) Impfstoffzusammensetzung
DK1420759T3 (da) Farmaceutiske sammensætninger til behandling af astma
NO20024175L (no) Azetidinderivater, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
NO20030713D0 (no) Oral faststoffdose vaksine
FI20105657A (fi) Farmaseuttisia koostumuksia
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
ITMI20010748A0 (it) Composizioni farmaceutiche
DK1309545T3 (da) Fremgangsmåde til fremstilling af alkylarylsulfonater
AU2003246373A8 (en) Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions
DK1309581T3 (da) Fremgangsmåde til fremstilling af citalopram
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
NO20026123L (no) Farmasöytiske sammensetninger
FI20011889A0 (fi) Menetelmä ksylitolin valmistamiseksi
EE200200252A (et) Antikehade kasutamine vaktsiinidena, antikehi sisaldavad farmatseutilised kompositsioonid, meetod antikehapreparaadi valmistamiseks ja meetod farmatseutilise kompositsiooni valmistamiseks
DK1296970T3 (da) Fremgangsmåde til fremstilling af citalopram
ITMI20001695A0 (it) Procedimento per la preparazione di composizioni organico-sili-coniche.